US Stock MarketDetailed Quotes
PMN ProMIS Neurosciences
- 1.040
- +0.080+8.33%
Close Jan 3 16:00 ET
- 1.030
- -0.010-0.95%
Post 20:01 ET
34.00MMarket Cap26.00P/E (TTM)
1.040High0.961Low71.66KVolume1.000Open0.960Pre Close71.33KTurnover0.42%Turnover RatioLossP/E (Static)32.69MShares3.10052wk High4.68P/B17.86MFloat Cap0.87052wk Low--Dividend TTM17.17MShs Float9.800Historical High--Div YieldTTM8.24%Amplitude0.870Historical Low0.995Avg Price1Lot Size
ProMIS Neurosciences Stock Forum
Sign in to post a comment
$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
28
9
7
$ProMIS Neurosciences (PMN.US)$
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
ProMIS Neurosciences (Nasdaq: PMN) will present preclinical data on its lead product candidate, PMN310, at the 4th International Conference on Cognitive & Behavioral Neurosciences. The data supports PMN310's potential as an Alzheimer's dise...
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
ProMIS Neurosciences (Nasdaq: PMN) will present preclinical data on its lead product candidate, PMN310, at the 4th International Conference on Cognitive & Behavioral Neurosciences. The data supports PMN310's potential as an Alzheimer's dise...
$ProMIS Neurosciences (PMN.US)$
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
ProMIS Neurosciences Inc. (Nasdaq: PMN) presented preclinical data at the 2024 Alzheimer's Association International Conference (AAIC) supporting their novel approach to optimizing an Alzheimer's disease (AD) vaccine. The company's proprietary computational platform identified four AβO-restricte...
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
ProMIS Neurosciences Inc. (Nasdaq: PMN) presented preclinical data at the 2024 Alzheimer's Association International Conference (AAIC) supporting their novel approach to optimizing an Alzheimer's disease (AD) vaccine. The company's proprietary computational platform identified four AβO-restricte...
2
$ProMIS Neurosciences (PMN.US)$
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
▪️ProMIS Neurosciences (Nasdaq: PMN) has reported positive top-line data from the first four cohorts of its Phase 1a clinical trial of PMN310 in healthy volunteers for Alzheimer's disease. The results showed:
▪️A favorable safety profile and tolerability across four ascending dose levels
▪️Dose-dependent levels of PMN310 antibody in cerebrospinal fluid (CSF)
Potenti...
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
▪️ProMIS Neurosciences (Nasdaq: PMN) has reported positive top-line data from the first four cohorts of its Phase 1a clinical trial of PMN310 in healthy volunteers for Alzheimer's disease. The results showed:
▪️A favorable safety profile and tolerability across four ascending dose levels
▪️Dose-dependent levels of PMN310 antibody in cerebrospinal fluid (CSF)
Potenti...
3
6
$ProMIS Neurosciences (PMN.US)$
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
1
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
AddiBee0925 : Hey Jag. Just a heads up. If all goes as planned, the launch for SIDU and SpaceX is on the schedule for this Friday on the 20th. I wouldn't think that it would be rescheduled so soon to the launch, at least no report has said otherwise.
Jaguar8 OP AddiBee0925 : Yes. But there might be a build up of the price before the launch just like LUNR. Hopefully it goes well.
AddiBee0925 Jaguar8 OP : yeah I'm thinking the same
Jaguar8 OP browny_440 : TNXP will be good if FDA releases decision soon
72306783 : I would like to ask, what signals or standards do you use to start building positions? I am still learning... Thank you very much for your Share
View more comments...